3 results on '"van Wijngaerden, Eric"'
Number of results to display per page
Search Results
2. Patterns of transmitted HIV drug resistance in Europe vary by risk group
- Author
-
Frentz, D., Van De Vijver, D., Abecasis, A. B., Albert, Jan, Hamouda, O., Jørgensen, L., Kücherer, C., Struck, D., Schmit, J. -C, Vercauteren, J., Åsjö, Birgitta, Balotta, Claudia, Bergin, C., Beshkov, Danail, Camacho, Ricardo J., Clotet, B., Griskevicius, A., Grossman, Z., Horban, A., Kolupajeva, T., Korn, K., Kostrikis, Leontios G., Linka, K. L. M., Nielsen, C., Otelea, D., Paraskevis, Dimitrios N., Paredes, R., Poljak, M., Puchhammer-Stöckl, E., Sönnerborg, A., Stanekova, D., Stanojevic, M., Vandamme, A. -M, Boucher, C., Wensing, A., Kostrikis, Leontios G. [0000-0002-5340-7109], Paraskevis, Dimitrios [0000-0001-6167-7152], Frentz, D., van de Vijver, D., Abecasis, A., Albert, J., Hamouda, O., Jørgensen, L., Kücherer, C., Struck, D., Schmit, J., Vercauteren, J., Asjö, B., Balotta, C., Bergin, C., Beshkov, D., Camacho, R., Clotet, B., Griskevicius, A., Grossman, Z., Horban, A., Kolupajeva, T., Korn, K., Kostrikis, L., Linka, K., Nielsen, C., Otelea, D., Paraskevis, D., Paredes, R., Poljak, M., Puchhammer-Stöckl, E., Sönnerborg, A., Stanekova, D., Stanojevic, M., Vandamme, A., Wensing, A., and Tramuto, F. among SPREAD Programme investigators, Graduate School, Sluis-Cremer, Nicolas, Van Wijngaerden, Eric, Virology, and Erasmus MC other
- Subjects
Male ,Epidemiology ,genotype ,Human immunodeficiency virus 1 ,HIV Infections ,RNA directed DNA polymerase inhibitor ,high risk patient ,Logistic regression ,Settore MED/42 - Igiene Generale E Applicata ,Men who have sex with men ,0302 clinical medicine ,Immunodeficiency Viruses ,middle aged ,statistics and numerical data ,10. No inequality ,Substance Abuse, Intravenous ,0303 health sciences ,adult ,transmission ,virus diseases ,virus transmission ,highly active antiretroviral therapy ,HIV immunopathogenesis ,3. Good health ,Medical Microbiology ,Viral Pathogens ,high risk behavior ,Medicine ,Science & Technology - Other Topics ,POPULATIONS ,health program ,anti human immunodeficiency virus agent ,USERS ,medicine.medical_specialty ,Science ,Sexual Behavior ,Immunology ,Sexually Transmitted Diseases ,intravenous drug abuse ,Microbiology ,03 medical and health sciences ,Antibiotic resistance ,SDG 3 - Good Health and Well-being ,Human immunodeficiency virus infection ,proteinase inhibitor ,Humans ,Protease Inhibitors ,human ,Heterosexuality ,Microbial Pathogens ,seroconversion ,Medicine and health sciences ,Science & Technology ,Genitourinary Infections ,MUTATIONS ,Virology ,major clinical study ,Logistic Models ,transmitted drug resistance mutation ,HIV-1 ,Viral Diseases ,Medical sciences: 700::Basic medical, dental and veterinary sciences: 710::Medical immunology: 716 [VDP] ,drug response ,men who have sex with men ,Drug resistance ,Clinical immunology ,geography ,APPEARANCE ,male homosexuality ,Medizinische Fakultät ,immune system diseases ,INFECTION ,Medicine and Health Sciences ,substance abuse ,030212 general & internal medicine ,risk ,Multidisciplinary ,ACTIVE ANTIRETROVIRAL THERAPY ,Transmission (medicine) ,virus mutation ,article ,Obstetrics and Gynecology ,HIV diagnosis and management ,Middle Aged ,virology ,Multidisciplinary Sciences ,Europe ,Infectious Diseases ,female ,Medisinske fag: 700::Basale medisinske, odontologiske og veterinærmedisinske fag: 710::Medisinsk immunologi: 716 [VDP] ,Reverse Transcriptase Inhibitors ,HIV clinical manifestations ,Female ,epidemiology ,blood sampling ,HIV drug resistance ,Research Article ,Adult ,Risk ,risk-group ,Anti-HIV Agents ,Urology ,prevalence ,Infectious Disease Epidemiology ,sexual behavior ,Risk-Taking ,male ,antiviral resistance ,Internal medicine ,Drug Resistance, Viral ,medicine ,controlled study ,ddc:610 ,Homosexuality, Male ,030304 developmental biology ,drug resistance ,Biology and life sciences ,business.industry ,statistical model ,HIV ,CD4 lymphocyte count ,heterosexuality ,nonnucleoside reverse transcriptase inhibitor ,Human immunodeficiency virus 1 infection ,Diagnostic medicine ,INDIVIDUALS ,drug effects ,Women's Health ,business ,trend study - Abstract
BACKGROUND: In Europe, a continuous programme (SPREAD) has been in place for ten years to study transmission of drug resistant HIV. We analysed time trends of transmitted drug resistance mutations (TDRM) in relation to the risk behaviour reported. METHODS: HIV-1 patients newly diagnosed in 27 countries from 2002 through 2007 were included. Inclusion was representative for risk group and geographical distribution in the participating countries in Europe. Trends over time were calculated by logistic regression. RESULTS: From the 4317 patients included, the majority was men-having-sex-with-men -MSM (2084, 48%), followed by heterosexuals (1501, 35%) and injection drug users (IDU) (355, 8%). MSM were more often from Western Europe origin, infected with subtype B virus, and recently infected (
- Published
- 2014
3. Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe
- Author
-
Moutschen, M., Frentz, D., Van de Vijver, D. A. M. C., Abecasis, A. B., Albert, Jan, Hamouda, O., Jørgensen, L. B., Ku¨cherer, C., Struck, D., Schmit, J. -C, Vercauteren, J., A˚sjo¨, B., Balotta, Claudia, Beshkov, Danail, Camacho, Ricardo J., Clotet, B., Coughlan, S., Griskevicius, A., Grossman, Z., Horban, A., Kolupajeva, T., Korn, K., Kostrikis, Leontios G., Liitsola, K., Linka, M., Nielsen, C., Otelea, D., Paraskevis, Dimitrios N., Paredes, R., Poljak, M., Puchhammer, Stockl E., So¨nnerborg, A., Stanekova, D., Stanojevic, M., Van Wijngaerden, E., Wensing, A. M. J., Boucher, C. A. B., Sarcletti, M., Schmied, B., Geit, M., Balluch, G., Vandamme, A. -M, Derdelinckx, I., Sasse, A., Bogaert, M., Ceunen, H., De Roo, A., De Wit, S., Echahidi, F., Fransen, K., Goffard, J. -C, Goubau, P., Goudeseune, E., Yombi, J. -C, Lacor, P., Liesnard, C., Pierard, D., Rens, R., Schrooten, Y., Vaira, D., Vandekerckhove, L. P. R., Van den Heuvel, A., Van Der Gucht, B., Van Ranst, M., Vandercam, B., Vekemans, M., Verhofstede, C., Clumeck, N., Van Laethem, K., Demetriades, Ioannis, Kousiappa, Ioanna, Demetriou, Victoria L., Hezka, Johana, Bruckova, M., Machala, L., Gerstoft, J., Mathiesen, L., Pedersen, C., Nielsen, H., Laursen, A., Kvinesdal, B., Salminen, M., Ristola, M., Suni, J., Sutinen, J., Berg, T., Braun, P., Poggensee, G., Da¨umer, M., Eberle, J., Heiken, H., Kaiser, R., Knechten, H., Mu¨ller, H., Neifer, S., Schmidt, B., Walter, H., Gunsenheimer-Bartmeyer, B., Harrer, T., Hatzakis, Angelos E., Magiorkinis, Emmanouil N., Hatzitheodorou, Eleni, Haida, Catherine, Zavitsanou, Assimina, Magiorkinis, Gkikas, Lazanas, Marios C., Chini, Maria C., Magafas, N., Tsogas, Nickolaos, Paparizos, Vassilios A., Kourkounti, Sofia, Antoniadou, Anastasia C., Papadopoulos, Antonios I., Panagopoulos, Periklis, Poulakou, Garyphallia G., Sakka, V., Chryssos, Georgios, Drimis, Stylianos, Gargalianos, Panagiotis, Lelekis, Moyssis I., Chilomenos, G., Psichogiou, Mina A., Daikos, George L., Panos, George, Haratsis, G., Kordossis, Theodore, Kontos, Athanasios N., Koratzanis, Georgios, Theodoridou, Maria C., Mostrou, Glykeria J., Spoulou, Vana I., De Gascun, C., Byrne, C., Duffy, M., Bergin, C., Reidy, D., Farrell, G., Lambert, J., O'Connor, E., Rochford, A., Low, J., Coakely, P., O'Dea, S., Hall, W., Levi, I., Chemtob, D., Riva, C., Mussini, C., Caramma, I., Capetti, A., Colombo, M. C., Rossi, C., Prati, F., Tramuto, F., Vitale, F., Ciccozzi, M., Angarano, G., Rezza, G., Schmit, J. C., Hemmer, R., Arendt, V., Staub, T., Schneider, F., Roman, F., van Kessel, A., van Bentum, P. H. M., Brinkman, K., op de Coul, E. L., van der Ende, M. E., Hoepelman, I., van Kasteren, M., Juttmann, J., Kuipers, M., Langebeek, N., Richter, C., Santegoets, R., Schrijnders-Gudde, L., Schuurman, R., van de Ven, B. J. M., Ormaasen, V., Aavitsland, P., Stanczak, J. J., Stanczak, G. P., Firlag-Burkacka, E., Wiercinska-Drapalo, A., Jablonowska, E., Malolepsza, E., Leszczyszyn-Pynka, M., Szata, W., Palma, C., Borges, F., Paixa&tild, o, T., Duque, V., Araújo, F., Jevtovic, D., Salemovic, D., Habekova, M., Mokráš, Miloš, Truska, P., Lunar, M., Babic, Dunja Z., Tomazic, J., Vidmar, L., Vovko, T., Karner, P., Domingo, P., Galindo, M. J., Miralles, C., del Pozo, M. A., Ribera, E., Iribarren, J. A., Ruiz, L., de la Torre, J., Vidal, F., Garcia, F., Heidarian, A., Aperia-Peipke, K., Axelsson, M., Mild, M., Karlsson, A., Thalme, A., Nave´r, L., Bratt, G., Blaxhult, A., Gissle´n, M., Svennerholm, B., Bergbrant, I., Björkman, Per, Sa¨ll, C., Mellgren, A˚, Lindholm, A., Kuylenstierna, N., Montelius, R., Azimi, F., Johansson, B., Carlsson, M., Johansson, E., Ljungberg, B., Ekvall, H., Strand, A., Ma¨kitalo, S., o¨berg, S., Holmblad, P., Ho¨fer, M., Holmberg, H., Josefson, P., Ryding, U., Van Kessel, A., Kostrikis, Leontios G. [0000-0002-5340-7109], Paraskevis, Dimitrios [0000-0001-6167-7152], Virology, Erasmus MC other, Frentz, Dineke, Van de Vijver, David A.M.C., Abecasis, Ana B., Albert, Jan, Hamouda, Osamah, Jørgensen, Louise B., Ku¨cherer, Claudia, Struck, Daniel, Schmit, Jean-Claude, Vercauteren, Jurgen, A˚sjo¨, Birgitta, Balotta, Claudia, Beshkov, Danail, Camacho, Ricardo J., Clotet, Bonaventura, Coughlan, Suzie, Griskevicius, Algirda, Grossman, Zehava, Horban, Andrzej, Kolupajeva, Tatjana, Korn, Klau, Kostrikis, Leondios G., Liitsola, Kirsi, Linka, Marek, Nielsen, Clau, Otelea, Dan, Paraskevis, Dimitrio, Paredes, Roger, Poljak, Mario, Puchhammer-Sto¨ckl, Elisabeth, So¨nnerborg, Ander, Stanekova, Danica, Stanojevic, Maja, Van Wijngaerden, Eric, Wensing, Annemarie M.J., Boucher, Charles A.B., SPREAD programme investigators, including Vitale F and Tramuto F., Graduate School, UCL - SSS/IREC/MBLG - Pôle de Microbiologie médicale, UCL - (SLuc) Service de microbiologie, UCL - (SLuc) Service de médecine interne générale, UCL - (SLuc) Service d'hématologie, Clinicum, and Department of Medicine
- Subjects
Male ,virus strain ,Resistance ,HIV Infections ,Drug resistance ,THERAPY ,Nucleoside Reverse Transcriptase Inhibitor ,ANTIRETROVIRAL DRUG-RESISTANCE ,0302 clinical medicine ,Medical microbiology ,Genotype ,Medicine and Health Sciences ,Prevalence ,HIV Infection ,030212 general & internal medicine ,UNITED-KINGDOM ,Phylogeny ,0303 health sciences ,Communicable disease ,Transmission (medicine) ,adult ,virus mutation ,UPDATED RECOMMENDATIONS ,virus transmission ,3. Good health ,Europe ,Infectious Diseases ,female ,risk factor ,virus resistance ,Female ,NAIVE PATIENTS ,SOCIETY-USA PANEL ,Research Article ,Human ,Adult ,medicine.medical_specialty ,Anti-HIV Agents ,Virus ,Article ,03 medical and health sciences ,SDG 3 - Good Health and Well-being ,male ,MOLECULAR EPIDEMIOLOGY ,Drug Resistance, Viral ,medicine ,proteinase inhibitor ,Humans ,Transmission ,controlled study ,human ,molecular phylogeny ,030304 developmental biology ,nonhuman ,MUTATIONS ,business.industry ,Anti-HIV Agent ,nucleotide sequence ,nonnucleoside reverse transcriptase inhibitor ,Human immunodeficiency virus 1 infection ,Virology ,major clinical study ,unindexed sequence ,Parasitology ,3121 General medicine, internal medicine and other clinical medicine ,Mutation ,HIV-1 ,business - Abstract
Background: One out of ten newly diagnosed patients in Europe was infected with a virus carrying a drug resistant mutation. We analysed the patterns over time for transmitted drug resistance mutations (TDRM) using data from the European Spread program.Methods: Clinical, epidemiological and virological data from 4317 patients newly diagnosed with HIV-1 infection between 2002 and 2007 were analysed. Patients were enrolled using a pre-defined sampling strategy.Results: The overall prevalence of TDRM in this period was 8.9% (95% CI: 8.1-9.8). Interestingly, significant changes over time in TDRM caused by the different drug classes were found. Whereas nucleoside resistance mutations remained constant at 5%, a significant decline in protease inhibitors resistance mutations was observed, from 3.9% in 2002 to 1.6% in 2007 (p = 0.001). In contrast, resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs) doubled from 2.0% in 2002 to 4.1% in 2007 (p = 0.004) with 58% of viral strains carrying a K103N mutation. Phylogenetic analysis showed that these temporal changes could not be explained by large clusters of TDRM.Conclusion: During the years 2002 to 2007 transmitted resistance to NNRTI has doubled to 4% in Europe. The frequent use of NNRTI in first-line regimens and the clinical impact of NNRTI mutations warrants continued monitoring. © 2014 Frentz et al. licensee BioMed Central Ltd. 14 Cited By :16
- Published
- 2014
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.